Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
UNLABELLED: The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, exendin-4 and liraglutide, suppress food intake and body weight. The mediating site(s) of action for the anorectic effects produced by peripheral administration of these GLP-1R agonists are not known. Experiments addressed whether food intake suppression after i.p. delivery of exendin-4 and liraglutide is mediated exclusively by peripheral GLP-1R or also involves direct central nervous system (CNS) GLP-1R activation. Results showed that CNS delivery [third intracerebroventricular (3(rd) ICV)] of the GLP-1R antagonist exendin-(9-39) (100 μg), attenuated the intake suppression by i.p. liraglutide (10 μg) and exendin-4 (3 μg), particularly at 6 h and 24 h. Control experiments show that these findings appear to be based neither on the GLP-1R antagonist acting as a nonspecific competing orexigenic signal nor on blockade of peripheral GLP-1R via efflux of exendin-(9-39) to the periphery. To assess the contribution of GLP-1R expressed on subdiaphragmatic vagal afferents to the anorectic effects of liraglutide and exendin-4, food intake was compared in rats with complete subdiaphragmatic vagal deafferentation and surgical controls after i.p. delivery of the agonists. Both liraglutide and exendin-4 suppressed food intake at 3 h, 6 h, and 24 h for controls; for subdiaphragmatic vagal deafferentation rats higher doses of the GLP-1R agonists were needed for significant food intake suppression, which was observed at 6 h and 24 h after liraglutide and at 24 h after exendin-4. CONCLUSION: Food intake suppression after peripheral administration of exendin-4 and liraglutide is mediated by activation of GLP-1R expressed on vagal afferents as well as direct CNS GLP-1R activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is consistent with some prior studies demonstrating a role for NTS GLP-1R neurons in physiological satiation/satiety and for some of the anorectic effects of various GLP-1RAs, with some reporting an absence of evidence of proxies for nausea (109‐113).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [110]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“The long-acting GLP-1R agonists, exendin-4 and liraglutide, are efficacious in the treatment of T2DM and may hold promise for the treatment of obesity (5, 6, 28).”
BackgroundOgden, C. L., Yanovski, S. Z., Carroll, M. D., & Flegal, K. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.052 · Cited by 1,561
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Abbott, C. R., Monteiro, M., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 599 · cited 1×
“Similarly, others also show that ip administration of GLP-1 does not suppress short-term intake after total subdiaphragmatic vagotomy (12), and ip exendin-4 does not suppress intake up to 8 h after administration in capsaicintreated mice (50).”
BackgroundAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Göke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Glucoreceptors Controlling Feeding and Blood Glucose: Location in the Hindbrain
Ritter, R. C., Slusser, P. G., & Stone, S. (1981) · Science · doi:10.1126/science.6264602 · Cited by 467 · cited 1×
“After a 7-d surgical recovery period, 3 ICV cannula placement was assessed by measurement of the sympathoadrenal-mediated hyperglycemic response to the cytoglucopenia induced by 5-thio-D-glucose (210 g in 2 l aCSF) (20).”
MethodGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416
Cited by
Items 101–200 of 345
Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects
Hayes, M. R. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.02.017 · Cited by 74
“Indeed, a recent report demonstrated that food intake suppression by IP administration of exendin-4 and liraglutide is mediated by both a vagal afferent-dependent, as well as a vagal afferent-independent pathway that likely involves blood–brain barrier (BBB) penetrance and subsequent direct CNS GLP-1R activation [12].”
Self-citationNeuromodulatory effects of anti-diabetes medications: A mechanistic review
Yaribeygi, H., Ashrafizadeh, M., Henney, N. C., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104611 · Cited by 69
Labouesse, M. A., Stadlbauer, U., Weber, E., Arnold, M., Langhans, W., & Pacheco‐López, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02364.x · Cited by 69
Self-citationVagal mediation of GLP-1's effects on food intake and glycemia
Krieger, J.-P., Langhans, W., & Lee, S. J. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.06.001 · Cited by 67
Cai, T., Zheng, S.-P., Shi, X., Yuan, L., Hu, H., Bai, Z., Xiao, S.-L., & Wang, F. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.900652 · Cited by 71
The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
Hayes, M. R., Borner, T., & De Jonghe, B. C. (2021) · Diabetes · doi:10.2337/dbi21-0004 · Cited by 64
“A wealth of literature indicates that a significant portion of the hypophagic effects of current GLP-1R agonists are mediated by GLP-1Rs expressed in the CNS, in particular those in the AP/NTS (37-42).”
BackgroundSelf-citationCentral GLP-1 receptors: Novel molecular targets for cocaine use disorder
Hernandez, N. S., & Schmidt, H. D. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.03.026 · Cited by 63
Asevedo, E. D. M., Rizzo, L. B., Gadelha, A., Mansur, R. B., Ota, V., Berberian, A. D. A., Scarpato, B. S., Teixeira, A. L., Bressan, R. A., & Brietzke, E. M. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.02.032 · Cited by 66
Ghosal, S., Packard, A. E. B., Mahbod, P., McKlveen, J. M., Seeley, R. J., Myers, B., Ulrich-Lai, Y., Smith, E. P., D'Alessio, D. A., & Herman, J. P. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1104-16.2016 · Cited by 63
“…on stress reactivity has been confounded by uncertainty about the extent to which gut-derived GLP-1 in the circulation crosses the blood– brain barrier to influence CNS functions (Kanoski et al., 2011), and the possibility of indirect effects from peripheral GLP-1 systems (Heppner et al., 2015).”
BackgroundThe role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes
Adamska, E., Ostrowska, L., Górska, M., & Krętowski, A. (2014) · Gastroenterology Review · doi:10.5114/pg.2014.42498 · Cited by 60
“Glucagon-like peptide-1, via the GLP-1 receptor in the central nervous system, shows also central effects, suppressing appetite and reducing the rate of food absorption into the blood by lowering the rate of gastric emptying [72–74].”
BackgroundEffects of liraglutide in hypothalamic arcuate nucleus of obese mice
Barreto‐Vianna, A. R. C., Aguila, M. B., & Mandarim‐de‐Lacerda, C. A. (2016) · Obesity · doi:10.1002/oby.21387 · Cited by 58
Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56
Douton, J. E., Horvath, N., Mills‐Huffnagle, S., Nyland, J. E., Hajnal, A., & Grigson, P. S. (2022) · Addiction Biology · doi:10.1111/adb.13117 · Cited by 54
The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
Zhang, L., Zhang, W., & Tian, X. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2021.1924707 · Cited by 54
Liver innervation and hepatic function: new insights
Kandilis, A. N., Papadopoulou, I. P., Koskinas, J. S., Sotiropoulos, G., & TINIAKOS, D. G. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.12.006 · Cited by 64
Duca, F. A., & Covașă, M. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512000529 · Cited by 59
“Indeed, recent work by Kanoski et al.((137)) shows that the suppressive effects of longlasting GLP-1 agonists are not exclusively mediated by a peripheral action, but also require some central activation, while others have shown that blood-borne GLP-1 does not require peripheral participation((138,139)).”
BackgroundPotential Link between Gut Microbiota and Deoxynivalenol-Induced Feed Refusal in Weaned Piglets
Wang, S., Yang, J., Zhang, B., Zhang, L., Wu, K., Ao, Y., Li, C., Wang, Y., Zhang, J., & Qi, D. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b01037 · Cited by 54
Suarez, A. N., Noble, E. E., & Kanoski, S. E. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00101 · Cited by 52
Self-citationTirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents
Geisler, C. E., Antonellis, M. P., Trumbauer, W., Martin, J. A., Coskun, T., Samms, R. J., & Hayes, M. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14843 · Cited by 51
Self-citationBasal Insulin Intensification in Patients with Type 2 Diabetes: A Review
Meece, J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0395-3 · Cited by 51
“In addition, they have been shown to inhibit gastric acid secretion, slow gastric emptying, and, by interactions with the central nervous system, increase satiety, resulting in reduced food intake and therefore reduced glucose input [26, 27].”
BackgroundTargeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Herman, R. J., & Schmidt, H. D. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114565 · Cited by 62
Is the Brain a Key Player in Glucose Regulation and Development of Type 2 Diabetes?
Lundqvist, M., Almby, K. E., Abrahamsson, N., & Eriksson, J. W. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00457 · Cited by 60
Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss
Liberini, C. G., Koch-Laskowski, K., Shaulson, E., McGrath, L. E., Lipsky, R. K., Lhamo, R., Ghidewon, M., Ling, T., Stein, L. M., & Hayes, M. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-44591-8 · Cited by 50
Self-citationThe Role of Glucagon-Like Peptide-1 in Energy Homeostasis
Salehi, M., & Purnell, J. Q. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0088 · Cited by 46
Borner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & De Jonghe, B. C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 49
Self-citationChen, Z., Deng, X., Shi, C., Jing, H., Tian, Y., Zhong, J., Chen, G., Xu, Y., Luo, Y., & Zhu, Y. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178239 · Cited by 48
Effects of newly introduced antidiabetic drugs on autophagy
Ashrafizadeh, M., Yaribeygi, H., Atkin, S. L., & Sahebkar, A. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.06.028 · Cited by 51
Glucagon-Like Peptide 1 in the Brain: Where Is It Coming From, Where Is It Going?
Daniels, D., & Mietlicki-Baase, E. G. (2019) · Diabetes · doi:10.2337/dbi18-0045 · Cited by 46
“Food and Drug Administration– approved GLP-1R agonists act in the body, it is critical to keep in mind that the long-acting GLP-1R agonists exendin4 and liraglutide can penetrate the central nervous system and access blood-brain barrier–protected sites to influence GLP-1–mediated responses such as food intake and body…”
BackgroundTsai, W.-H., Sung, F.-C., Chiu, L.-T., Shih, Y.-H., Tsai, M.-C., & Wu, S.-I. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.765446 · Cited by 44
“However, research indicated that the intake-inhibitory effects of the GLP-1 RA, exendin-4 and liraglutide, were mediated by activation of GLP-1R expressed on sub-diaphragmatic vagal afferents as well as in the brain (Kanoski et al., 2011).”
BackgroundHu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43
“One study conducted two experiments demonstrating that the activation of GLP-1 in the subdiaphragmatic vagal afferents and the brain contributes to the intake-inhibitory effects of GLP-1 RAs [23].”
BackgroundZhu, E., Yang, Y., Zhang, J., Li, Y., Li, C., Chen, L., & Sun, B. (2016) · Oncotarget · doi:10.18632/oncotarget.13189 · Cited by 42
“The previously known mechanisms of liraglutide effect on weight loss are suppression of appetite and inhibition of food intake through hypothalamic or parasympathetic pathways [37].”
BackgroundPeripheral neural targets in obesity
Page, A. J., Symonds, E., Peiris, M., Blackshaw, L. A., & Young, R. L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01951.x · Cited by 43
“In rats, this reduced food intake with liraglutide is due to combined actions at GLP-1 receptors on peripheral vagal afferents of the intestine (or hepatic portal region) and centrally (Kanoski et al., 2011).”
BackgroundZheng, H., Reiner, D. J., Hayes, M. R., & Rinaman, L. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.2180-18.2019 · Cited by 40
“…that forebrain GLP1Rs are unnecessary for systemic Ex4-induced hypophagia in rats (Hayes et al., 2008), we also detected no difference between CTRL and GLP1R-KD rats in their hypophagic response to systemic Ex4, which suppresses food intake via vagal and central GLP1Rs (Kanoski et al., 2011).”
BackgroundInfluentialSelf-citationWoo, Y. S., Lim, H. K., Wang, S., & Bahk, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186969 · Cited by 47
“It is also well established that GLP-1 acts as a neuropeptide that provides glycemic homeostasis [187] and appetite/food intake control [188].”
BackgroundGLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
Fortin, S. M., Chartoff, E. H., & Roitman, M. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.220 · Cited by 45
Self-citationZüger, D., Forster, K., Lutz, T. A., & Riediger, T. (2013) · Physiology & Behavior · doi:10.1016/j.physbeh.2013.02.006 · Cited by 40
“Both exogenous GLP-1 and the GLP-1R agonist exendin-4 induce a c-Fos response in the AP [15] and both peptides reduce meal size in rats [16].”
BackgroundKanoski, S. E., Ong, Z. Y., Fortin, S. M., Schlessinger, E. S., & Grill, H. J. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12423 · Cited by 40
“Given that acute liraglutide reduces food intake via activation of both peripheral and central GLP-1 receptors after peripheral administration [40,45], it is possible that the meal pattern effects observed in the present study are mediated by an action in the periphery, centrally, or both.”
BackgroundSelf-citationCorrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
Borner, T., Workinger, J. L., Tinsley, I. C., Fortin, S. M., Stein, L. M., Chepurny, O. G., Holz, G. G., Wierzba, A. J., Gryko, D., Nexø, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107768 · Cited by 39
Self-citationParabrachial Nucleus Contributions to Glucagon-Like Peptide-1 Receptor Agonist-Induced Hypophagia
Swick, J., Alhadeff, A. L., Grill, H. J., Urrea, P., Lee, S. M., Roh, H., & Baird, J.-P. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.50 · Cited by 37
Self-citationHe, M., Guan, N., Gao, W.-W., Liu, Q., Wu, X.-Y., Ma, D.-W., Zhong, D.-F., Ge, G.-B., Li, C., Chen, X.-Y., et al. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.169 · Cited by 36
Hansen, H. H., Hansen, G., Paulsen, S. J., Vrang, N., Mark, M., Jelsing, J., & Klein, T. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.010 · Cited by 42
“For example, native GLP-1/GLP-1 agonists and GLP-1 receptor antagonists are anorectic and orexigenic, respectively, when administered into the cerebral ventricles (Tang-Christensen et al., 1996; Barrera et al., 2009; Kanoski et al., 2011).”
BackgroundPlasticity of gastrointestinal vagal afferent satiety signals
Page, A. J., & Kentish, S. J. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12973 · Cited by 40
High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats
Mul, J. D., Begg, D. P., Barrera, J. G., Li, B., Matter, E. K., D'Alessio, D. A., Woods, S. C., Seeley, R. J., & Sandoval, D. A. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00588.2012 · Cited by 37
“However, pharmacological ablation of afferent C-type neural fibers using a capsaicin approach or a subdiaphragmatic vagal deafferentation approach partially blocks the ability of peripheral Ex4 to reduce food intake (27, 33, 46).”
BackgroundResultRupprecht, L. E., Mietlicki-Baase, E. G., Zimmer, D. J., McGrath, L. E., Olivos, D. R., & Hayes, M. R. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00367.2013 · Cited by 37
Self-citationMietlicki‐Baase, E. G., Liberini, C. G., Workinger, J. L., Bonaccorso, R. L., Borner, T., Reiner, D. J., Koch‐Laskowski, K., McGrath, L. E., Lhamo, R., Stein, L. M., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13222 · Cited by 36
Self-citationBenefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Sandsdal, R. M., Juhl, C. R., & Torekov, S. S. (2019) · Drug Safety · doi:10.1007/s40264-019-00812-7 · Cited by 40
Holt, M. K., Cook, D. R., Brierley, D. I., Richards, J. E., Reimann, F., Gourine, A. V., Marina, N., & Trapp, S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101024 · Cited by 35
“The doses of GLP-1 (100 μg/kg) and Ex4 (10 μg/kg) were chosen based on previous studies reporting significant effects on f od intake [45-49].”
MethodMoving beyond energy homeostasis: New roles for glucagon-like peptide-1 in food and drug reward
Reddy, I. A., Stanwood, G. D., & Galli, A. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2013.10.003 · Cited by 35
“It is also possible that endogenous GLP-1 or its long-lasting analogues are influencing central signaling through vagal transmission (Abbott et al., 2005; Kakei et al., 2002; Kanoski et al., 2011; Rinaman, 2010; Williams, 2009).”
Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea
De Jonghe, B. C., Holland, R. A., Olivos, D. R., Rupprecht, L. E., Kanoski, S. E., & Hayes, M. R. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.10.031 · Cited by 35
Self-citationEstradiol modulates the anorexic response to central glucagon-like peptide 1
Maske, C. B., Jackson, C. M., Terrill, S. J., Eckel, L. A., & Williams, D. L. (2017) · Hormones and Behavior · doi:10.1016/j.yhbeh.2017.05.012 · Cited by 35
Skovbjerg, G., Roostalu, U., Salinas, C. G., Skytte, J. L., Perens, J., Clemmensen, C., Elster, L., Frich, C. K., Hansen, H. H., & Hecksher‐Sørensen, J. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109637 · Cited by 32
Loss-of-function mutations in ADCY3 cause monogenic severe obesity
Saeed, S., Bonnefond, A., Tamanini, F., Mirza, M. U., Manzoor, J., Janjua, Q. M., Din, S. M., Gaitan, J., Milochau, A., Durand, E., et al. (2018) · Yearbook of pediatric endocrinology · doi:10.1530/ey.15.11.5 · Cited by 35
GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential
Moaket, O. S., Obaid, S. E., Obaid, F. E., Shakeeb, Y. A., Elsharief, S. M., Tania, A., Darwish, R., Butler, A. E., & Moin, A. S. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110743 · Cited by 46
Extra-pancreatic effects of incretin-based therapies
Gallwitz, B. (2014) · Endocrine · doi:10.1007/s12020-014-0223-0 · Cited by 35
Wang, X., Ding, Z., Yang, F., Dai, Y., Chen, P., Theus, S. A., Singh, S. P., Budhiraja, M., & Mehta, J. L. (2016) · Clinical Science · doi:10.1042/cs20160061 · Cited by 33
Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides
Sekar, R., Wang, L., & Chow, B. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00018 · Cited by 35
Wan, Y., Bao, X., Huang, J., Zhang, X., Liu, W., Cui, Q., Jiang, D., Wang, Z., Liu, R., & Wang, Q. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00294 · Cited by 38
“…a regulatory effect on the energy expenditure of the obese mice, which is in good agreement with previous studies in both preclinical and clinical obese subjects (Kanoski et al., 2011; Fukuda-Tsuru et al., 2014; Shah and Vella, 2014; Decara et al., 2016; Rondanelli et al., 2016; Xu et al., 2016).”
ResultAnand, U., Yiangou, Y., Akbar, A., Quick, T., MacQuillan, A. H. F., Fox, M., Sinisi, M., Korchev, Y. E., Jones, B. J., Bloom, S. R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198024 · Cited by 35
Fortin, S. M., Chen, J. C., Petticord, M. C., Ragozzino, F. J., Peters, J. H., & Hayes, M. R. (2023) · Science Advances · doi:10.1126/sciadv.adh0980 · Cited by 32
“Rats were also tested with the GLP-1R antagonist, exendin (9-39) (Ex-9), to investigate an endogenous contribution of LC GLP-1R signaling to feeding behavior.”
BackgroundMethodSelf-citationFarokhnia, M., Fede, S. J., Grodin, E. N., Browning, B. D., Crozier, M. E., Schwandt, M. L., Hodgkinson, C. A., Momenan, R., & Leggio, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-17190-3 · Cited by 32
“For rs6923761, three ICs (21, 35, 47) showed significant genotype × AUDIT interaction effects on within-network connectivity.”
BackgroundInfluentialBoland, B. B., Laker, R. C., O'Brien, S., Sitaula, S., Sermadiras, I., Nielsen, J. C., Barkholt, P., Roostalu, U., Hecksher‐Sørensen, J., Sejthen, S. R., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101392 · Cited by 43
Han, J. D. J., Wang, Y., Meng, Q., Li, G., Huang, F., Wu, S., Fei, Y., Zhou, F. L., & Fu, J. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.032 · Cited by 32
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
“Hypotha-lamic feeding centers express GLP-1 and/or GLP-1R, which has a direct impact on hunger and weight reduction [119,120].”
Semaglutide effects on energy balance are mediated by Adcyap1+ neurons in the dorsal vagal complex
Teixidor-Deulofeu, J., Sköldheden, S. B., Font‐Gironès, F., Feješ, A., Ruud, J., & Engström, L. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.04.018 · Cited by 38
Mechanistic insights into the liver–brain axis during chronic liver disease
Siddle, M. R., Durán, R. G., Goel, D., Renquist, B. J., Holt, M. K., & Hadjihambi, A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01142-z · Cited by 41
The diverse effects of brain glucagon‐like peptide 1 receptors on ingestive behaviour
Williams, D. L. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15535 · Cited by 34
“Blockade or knockout of GLP-1 receptors in the CNS can attenuate the hypophagic effect of peripheral degradation-resistant agonist treatment (Kanoski et al., 2011; Sisley et al., 2014), suggesting that stimulation of the brain GLP-1 receptors plays some role in the feeding response.”
BackgroundWen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s312527 · Cited by 30
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Złotek, M., Kurowska, A., Herbet, M., & Piątkowska‐Chmiel, I. (2023) · Biomedicines · doi:10.3390/biomedicines11113035 · Cited by 32
“GLP-1 receptors are widely distributed in the body, expressed on pancreatic beta cells and neurons of the central and peripheral nervous system [126–128].”
BackgroundGlucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons
Iwasaki, Y., Goswami, C., & Yada, T. (2017) · Neuropeptides · doi:10.1016/j.npep.2017.05.003 · Cited by 34
Leon, R. M., Borner, T., Reiner, D. J., Stein, L. M., Lhamo, R., Jonghe, B. C. D., & Hayes, M. R. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0384-x · Cited by 28
Self-citationFang, X., Du, Z., Duan, C., Zhan, S., Wang, T., Zhu, M., Shi, J., Meng, J., Zhang, X., Yang, M., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118966 · Cited by 29
Park, K.-A., Jin, Z. H., Lee, J. Y., An, H. S., Choi, E. B., Kim, K. E., Shin, H. J., Jeong, E. A., Min, K. A., Shin, M. C., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020159 · Cited by 30
“In the peripheral nervous system, GLP-1R agonists, including exendin-4 and liraglutide, cause suppression of food intake via subdiaphragmatic vagal deafferentation [32].”
BackgroundJessen, L., Aulinger, B. A., Hassel, J. L., Roy, K. J., Smith, E. P., Greer, T. M., Woods, S. C., Seeley, R. J., & D'Alessio, D. A. (2012) · Endocrinology · doi:10.1210/en.2012-1358 · Cited by 29
Wang, X., Chen, J., Rong, C., Pan, F., Zhao, X., & Hu, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.10.197 · Cited by 30
Synthesis, Characterization and Pharmacodynamics of Vitamin‐B12‐Conjugated Glucagon‐Like Peptide‐1
Clardy‐James, S., Chepurny, O. G., Leech, C. A., Holz, G. G., & Doyle, R. P. (2012) · ChemMedChem · doi:10.1002/cmdc.201200461 · Cited by 29
Liraglutide ameliorates lipotoxicity-induced inflammation through the mTORC1 signalling pathway
Ao, N., Ma, Z., Yang, J., Jin, S., Zhang, K., Luo, E., & Du, J. (2020) · Peptides · doi:10.1016/j.peptides.2020.170375 · Cited by 30
Deoxynivalenol (Vomitoxin)-Induced Anorexia Is Induced by the Release of Intestinal Hormones in Mice
Yue, J., Guo, D., Gao, X., Wang, J., Nepovimová, E., Wu, W., & Kuča, K. (2021) · Toxins · doi:10.3390/toxins13080512 · Cited by 30
“GLP-1 was first discovered as an incretin, which can prevent hyperglycemia by enhancing insulin secretion and inhibiting the secretion of glucagon [17].”
BackgroundKreisler, A. D., & Rinaman, L. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00243.2015 · Cited by 27
Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations
Liang, N.-C., Bello, N. T., & Moran, T. H. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.16 · Cited by 32
Genovese, S., Mannucci, E., & Ceriello, A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0499-6 · Cited by 33
“It also exerts an indirect action by activatingGLP-1 receptors expressed on vagal afferents [34].”
BackgroundExendin-4 reduces food intake via the PI3K/AKT signaling pathway in the hypothalamus
Yang, Y., Choi, P. P., Smith, W. W., Xu, W., Ma, D., Cordner, Z. A., Liang, N., & Moran, T. H. (2017) · Scientific Reports · doi:10.1038/s41598-017-06951-0 · Cited by 32
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
Kuthati, Y., Davuluri, V. N. G., & Wong, C. (2025) · Biomolecules · doi:10.3390/biom15050622 · Cited by 32
“This also demonstrates anti-inflammatory and anti-apoptotic properties, which are essential in neurodegenerative disorders [35,41,42].”
InfluentialThe gut sensor as regulator of body weight
Reinehr, T., & Roth, C. L. (2014) · Endocrine · doi:10.1007/s12020-014-0518-1 · Cited by 30
“blocking effects of central exendin 9–39 even on the effects of peripheral GLP-1 in rats [46].”
Targeting the gastrointestinal tract to treat type 2 diabetes
Bauer, P. V., & Duca, F. A. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0056 · Cited by 29
“GLP-1R antagonist, exendin-9, blocks the inhibitory effects of exenatide on energy intake in rodents (Kanoski et al. 2011).”
BackgroundDailey, M. J., Moghadam, A. A., & Moran, T. H. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00335.2011 · Cited by 29
“Centrally administered Ex 9 does attenuate the inhibitory effect on food intake of two longer-lasting agonists, Ex 4 and liraglutide, after intraperitoneal injection in rats (15).”
BackgroundLiu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Vilsbøll, T., Knop, F. K., & Holst, J. J. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00123.2015 · Cited by 25
“This has led to the hypothesis that endogenous GLP-1 may act locally, possibly via activation of vagal afferent fibers in the gastrointestinal tract, before being degraded (13), and findings in animal models support this hypothesis (15, 31, 39).”
ResultZeng, N., Cutts, E. J., Lopez, C. B., Kaur, S., Duran, M., VIRKUS, S., & Hardaway, J. A. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.724030 · Cited by 27
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
“Although GLP-1 signaling at vagal afferents may contribute to meal termination, expression here is not required for the weight-reducing effects of GLP-1R agonists ( 98 ).”
BackgroundThe (dys)regulation of energy storage in obesity
Levin, B. E., Geary, N., & Lutz, T. A. (2025) · Physiological Reviews · doi:10.1152/physrev.00002.2024 · Cited by 29
Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights
Alves, G. A. M., Teranishi, M., Ortega, A. C. T. D. C. G., James, F., & Arachchige, A. S. P. M. (2025) · Medical Sciences · doi:10.3390/medsci13030136 · Cited by 49
“Furthermore, vagotomy or pharmacological blockade of vagal transmission abolishes the effects of peripheral GLP-1RAs on reward behavior, underscoring the importance of intact gut–brain signaling [36].”
Masaki, T., Ozeki, Y., Yoshida, Y., Okamoto, M., Miyamoto, S., Gotoh, K., & Shibata, H. (2022) · Metabolites · doi:10.3390/metabo12020147 · Cited by 30
“In addition, the anorectic and anti-diabetic effects of GLP-1 are mediated by both the activation of GLP-1R expressed on vagal afferents and GLP-1R activation in the brain [21].”
BackgroundMetabolic factors in the regulation of hypothalamic innate immune responses in obesity
Folick, A., Cheang, R. T., Valdearcos, M., & Koliwad, S. K. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00666-z · Cited by 28
The role of food intake regulating peptides in cardiovascular regulation
Mikulášková, B., Maletínská, L., Zicha, J., & Kuneš, J. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.07.021 · Cited by 27
GLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 35
“Early studies showed that hindbrain GLP-1R blockade did not attenuate the appetite-suppressing effects of peripheral GLP-1 administration, and that vagotomy partially blocked the acute anorectic effect of peripheral GLP-1RA administration (88, 129, 130).”
Smits, M. M., & Holst, J. J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3699 · Cited by 26
Ripken, D., van der Wielen, N., van der Meulen, J., Schuurman, T., Witkamp, R. F., Hendriks, H., & Koopmans, S. J. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.11.031 · Cited by 26
“The GLP-1 receptor is expressed on enteric nerves, vagal nerve endings, and in the pancreas, stomach, small and large intestine, adipose tissue and brain [7,13].”
Borner, T., Shaulson, E. D., Tinsley, I. C., Stein, L. M., Horn, C. C., Hayes, M. R., Doyle, R. P., & Jonghe, B. C. D. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14089 · Cited by 25
Self-citation
Metadata
- Authors
- Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R.
- Affiliations
- University of Pennsylvania (US)
- ETH Zurich (CH)
- Corresponding author
- Kanoski, Scott E.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2011-06-21
- Volume
- 152
- Issue
- 8
- Pages
- 3103-3112
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC3138234
- OpenAlex
- W1965072462
- Cited by
- 347
- References
- 51
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 21 · 2023: 16 · 2022: 18 · 2021: 30 · 2020: 23 · 2019: 26 · 2018: 19 · 2017: 21 · 2016: 27 · 2015: 24 · 2014: 22 · 2013: 25 · 2012: 23
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrinology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (DK21397, DK089752)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK089752, DK085435, R01DK021397, F32DK089752, K01DK085435, DK 21397, R56DK021397)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, liraglutide, exendin-4, exendin-9-39, feeding inhibition, anorectic effect, vagal afferents, intracerebroventricular administration, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Animals, Appetite Depressants, Body Weight, Brain, Calcitonin, Eating, Male, Peptide Fragments, Peptides, Vagus Nerve, Venoms, Rats, Sprague-Dawley, Receptors, Glucagon, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.